Oncosil Medical (ASX:OSL) has appointed Tom Milicevic as chief financial officer and company secretary, effective immediately.
Milicevic brings specific financial expertise in medical device and biotech companies.
The hire is a pivotal one as the company transitions from a development focus to the commercialisation of its OncoSilTM localised radiation treatment for cancer.
Oncosil is progressing towards a Conformité Européenne (CE) Mark application for its OncoSil™ localised radiation treatment for cancer.
A decision in respect in respect to the CE Mark is expected in November.
OncoSil™ is an implantable nuclear medicine (radiotherapy) device that has been successfully piloted in pancreatic and liver cancer.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong.